Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with <scp>P</scp>hiladelphia chromosome–positive acute lymphoblastic leukemiaFarhad Ravandi, Hagop M. Kantarjian, Jörge E. Cortes et al.|Cancer|2015Cited by 227
Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaFarhad Ravandi, Hagop M. Kantarjian, Jeffrey L. Jorgensen et al.|British Journal of Haematology|2015Cited by 118
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 studyAlexandre Bazinet, Guillermo Garcia‐Manero, Faezeh Darbaniyan et al.|The Lancet Haematology|2022Cited by 85
Topoisomerase II inhibitors in AML: past, present, and futureMinas P. Economides, Naveen Pemmaraju, Deborah McCue et al.|Expert Opinion on Pharmacotherapy|2019Cited by 41
Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasmMinas P. Economides, Naveen Pemmaraju, Deborah McCue et al.|Expert Review of Clinical Pharmacology|2019Cited by 21